SLCO1B1 pharmacogenetic testing
SLCO1B1 pharmacogenetic testing looks at a gene that helps control how certain medications move from the blood into the liver. It is best known for its role in statin medication discussions.
Some SLCO1B1 variants can reduce transporter function. This may increase the amount of certain statins circulating in the blood and may affect the chance of developing statin-associated muscle symptoms.
The result does not show whether every statin will cause a problem. Its meaning depends on the transporter-function category, the specific statin, the dose, other medications, and the person’s clinical history.
What SLCO1B1 does in the body
The SLCO1B1 gene provides instructions for making a transporter called OATP1B1. This transporter helps move certain substances and medications from the bloodstream into liver cells.
When transporter function is reduced, some medications may remain at higher levels in the blood. This is why SLCO1B1 may appear in a pharmacogenetic report focused on statin response and muscle-related side effects.
Gene
SLCO1B1 is the name of the gene included in the pharmacogenetic panel.
Transporter
The gene helps produce OATP1B1, a transporter involved in moving certain statins into the liver.
Medication context
The result must be matched to the specific statin, dose, treatment goal, and other clinical factors.
How SLCO1B1 results may be described
An SLCO1B1 report may use genotype, diplotype, or transporter-function language. The exact wording can vary between laboratories, so the report should explain how the laboratory moved from the detected variants to the final interpretation.
Normal function
A normal-function result predicts typical activity of the OATP1B1 transporter based on the variants included in the test.
Decreased function
A decreased-function result predicts lower transporter activity. The importance of this result depends on the statin and dose being considered.
Poor function
A poor-function result predicts substantially reduced transporter activity and may be linked to higher exposure to selected statins.
Why the medication name matters
SLCO1B1 does not affect every statin in exactly the same way. The strength of the association, expected medication exposure, and available clinical guidance can differ between statins.
A result should therefore be reviewed with the complete statin pharmacogenetic testing guide rather than used as a stand-alone reason to begin, stop, or change treatment.
Which statin is involved?
Confirm whether the report is discussing simvastatin, atorvastatin, rosuvastatin, pravastatin, lovastatin, or another statin.
What dose is being considered?
Medication exposure and muscle-symptom risk can change with dose, so the dose should be part of the interpretation.
Are other genes included?
Some statin reports also consider markers such as ABCG2 or CYP2C9. Review the full panel instead of reading one gene in isolation.
Are other risk factors present?
Age, health conditions, medication interactions, previous symptoms, and treatment goals may still affect the clinical decision.
Questions worth asking about an SLCO1B1 result
What transporter-function category was assigned?
Ask whether the report predicts normal, decreased, or poor SLCO1B1 function and how that category was determined.
Does the result apply to my statin?
Confirm that the report includes guidance for the exact medication being used or considered.
What symptoms still require attention?
Genetic testing does not replace monitoring. Ask what muscle symptoms or other concerns should be reported during treatment.
What other factors affect the decision?
Review other prescriptions, supplements, previous statin experience, health conditions, and cholesterol treatment goals.
Does anything need to change?
The result may support a medication discussion, but it should not be used to change a prescription without clinical review.
What SLCO1B1 testing cannot tell you
It does not diagnose statin intolerance
The result estimates one genetic factor connected to statin exposure. It does not prove that current or future symptoms are caused by a statin.
It does not predict every side effect
SLCO1B1 is most often discussed in relation to statin exposure and muscle symptoms. It does not provide a complete prediction of every possible reaction.
It does not replace clinical monitoring
A normal-function result does not guarantee that symptoms will not occur, and a reduced-function result does not mean that every statin will cause a problem.
Useful SLCO1B1 testing resources
Learn how pharmacogenetic findings may be considered in medication-specific statin discussions.
Compare SLCO1B1 with metabolism, transport, immune-response, and other genes that may appear in a PGx panel.
Review how genotypes, predicted function, medication notes, and limitations may appear in a completed report.
Questions people ask about SLCO1B1 testing
What does SLCO1B1 pharmacogenetic testing tell me?
It predicts the function of a liver transporter that can affect exposure to selected statins. The finding becomes useful when matched to the specific medication and dose involved.
Is SLCO1B1 a metabolism gene?
It is more accurately described as a transporter gene. It helps control movement of certain medications from the bloodstream into liver cells rather than directly breaking the medication down.
Why does my report say decreased or poor function?
Those terms describe predicted OATP1B1 transporter activity based on the detected variants. They are not a diagnosis and must be connected to the statin being discussed.
Does reduced function mean I cannot take a statin?
No. The result may help inform medication selection, dose discussions, or monitoring, but it does not mean that all statins must be avoided.
Does a normal result mean I cannot develop muscle symptoms?
No. Genetic variation is only one factor. Dose, medication interactions, health conditions, exercise, and other non-genetic factors may also contribute.
Should I change my medication after reading this page?
No. Do not start, stop, or change a prescription based only on this page or one gene result. Review the complete report with a qualified healthcare professional.
What to verify before relying on the result
Variant coverage
Confirm which SLCO1B1 variants were tested and whether the laboratory explains how they were translated into a function category.
Statin-specific guidance
The report should connect the result to named medications instead of making broad statements about every cholesterol-lowering treatment.
Report and laboratory standards
Review the laboratory quality information and sample reports before selecting a test.
Review the process and your information choices
Follow the process from ordering and sample collection through laboratory analysis and report delivery.
Understand the permissions and acknowledgements connected to sample processing and report preparation.
Review how sample information, genetic data, accounts, and reports may be handled during testing.
Need help understanding SLCO1B1 within a broader PGx report?
Review the transporter-function category, specific statin, dose, other medications, and report limitations before deciding which questions to take to a healthcare professional.
Visit our homepage to explore pharmacogenetic testing, report guidance, privacy information, and other gene pages.
